
Opinion|Videos|June 15, 2024
Ruxolitinib Dosing and Platelet Count Considerations
Author(s)Prithviraj Bose, MD
Dr. Bose provides guidance on how he would approach ruxolitinib dosing if the patient's platelet count was 150 at week 12, including the potential use of the 5 mg tablet.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5


















